OncoMatch/Clinical Trials/NCT07283822
Amping up With PemJAK
Is NCT07283822 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Ruxolitinib and Pembrolizumab for non-hodgkin lymphoma.
Treatment: Ruxolitinib · Pembrolizumab — The purpose of this study is to understand and determine if ruxolitinib added to pembrolizumab is safe and effective for the treatment of relapsed or refractory Hodgkin and non-Hodgkin lymphomas.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Hodgkin Lymphoma
Biomarker criteria
Allowed: CD30 expression >10%
Other PTCL subtypes that express CD30 (>10%), must have received prior CD30-directed therapy.
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: CD30-directed therapy — systemic ALCL
Patients with systemic ALCL must have received prior CD30-directed therapy.
Must have received: CD30-directed therapy — PTCL subtypes with CD30 expression >10%
Other PTCL subtypes that express CD30 (>10%), must have received prior CD30-directed therapy.
Cannot have received: chemotherapy or immunotherapy
Exception: must not have received within 2 weeks prior to entering the study
Patients must not have had chemotherapy or immunotherapy within 2 weeks prior to entering the study
Lab requirements
Blood counts
ANC ≥ 1000/μL (not growth factor independent); Platelets ≥ 70,000/μL (or ≥50,000/mm3 if known bone marrow involvement with dose modifications allowed); Baseline hemoglobin level ≥ 8 g/dL (irrespective of bone marrow involvement)
Kidney function
Calculated creatinine clearance ≥ 30 ml/min using the Cockcroft-Gault formula
Liver function
Bilirubin ≤ 2 x ULN; AST ≤ 2.5 × ULN; ALT ≤ 2.5 × ULN
Organ function as assessed by laboratory testing and ECOG performance status 0-2 and or a Karnofsky performance score of equal or greater to 50
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Columbia University Irving Medical Center · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify